

From Medicaid on 2/19/24: Health Check Reimbursement for RSV Vaccine Administration

Reimbursement for Respiratory Syncytial Virus (RSV) Vaccine Administration

To address provider concerns related to the increased number of RSV cases and maternal RSV vaccination, the Department of Community Health (DCH) is allowing reimbursement for the administration of RSV vaccines. RSV vaccines protect infants and babies from becoming sicker from the virus. The two RSV vaccines, Beyfortus™ and Abrysvo, are available to Health Check providers via the Vaccines For Children (VFC) program. Reimbursement is also allowed on claims submitted for members 19 through 20 years of age.

Beyfortus

DCH allows reimbursement for new RSV vaccine administration codes 96380 and 96381 under the Health Check Program (COS 600). These new vaccine administration codes are covered for the administration of Beyfortus™ RSV monoclonal antibody vaccine and replaces the previously instructed generic CPT code 96372. For claims beginning with date of service March 1, 2024, Health Check providers should no longer report 96372 for the administration of Beyfortus™. Providers should report the new vaccine administration codes (96380 or 96381) with the EP modifier, along with the Beyfortus™ vaccine product codes (90380 or 90381) with the EP modifier.

Abrysvo

DCH allows reimbursement for the administration of the Abrysvo vaccine under the Health Check Program (COS 600). For claims beginning with date of service January 1, 2024, Health Check providers should code the Abrysvo product (CPT code 90678) with the EP modifier. Additionally, the Abrysvo product should be reported with the appropriate vaccine administration code (90460, 90471, 90472) with the EP modifier.

As always, we thank you for your participation in the Health Check program.